Gvia-M 50mg/500mg Tablets is primarily indicated in conditions like Type Il diabetes mellitus.
Gvia-M 50mg/500mg Tablets is contraindicated in conditions like Trauma, Insulin dependent diabetes mellitus, Type 1 diabetes mellitus, Diabetic ketoacidosis, Severe infections.
The severe or irreversible adverse effects of Gvia-M 50mg/500mg Tablets , which give rise to further complications include Fever, Pancreatitis, Hypersensitivity reactions, Chills, Peeling & redness of skin. Gvia-M 50mg/500mg Tablets produces potentially life-threatening effects which include Hypoglycemia, Hypoglycemia, Pancreatitis. which are responsible for the discontinuation of Gvia-M 50mg/500mg Tablets therapy. The signs and symptoms that are produced after the acute overdosage of Gvia-M 50mg/500mg Tablets include Tachycardia, Coma, Seizures, Drowsiness, Confusion, Hypoglycemia, Dizziness, Fainting, Sweating, Headache, Irritability, Tremor, Weakness. The symptomatic adverse reactions produced by Gvia-M 50mg/500mg Tablets are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Nausea, Diarrhea, Sore throat, Stomach upset, Stuffy nose.
Patients should be observed carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, Gvia-M 50mg/500mg Tablets should promptly be discontinued and appropriate management should be initiated. A dosage adjustment is recommended in patients with moderate or severe renal insufficiency and in patients with ESRD requiring hemodialysis or peritoneal dialysis. Use caution when used in conjunction with sulfonylureas; risk of hypoglycemia is increased. Monitor blood glucose closely; dosage adjustments of the sulfonylurea may be necessary. Safety and efficacy have not been established in children